Boehringer Ingelheim: CMOs, Biosimilars, R&D




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Boehringer Ingelheim: CMOs, Biosimilars, R&D
Released on: June 09, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Wolfgang Baiker, Corporate Divisions, operations and biopharmaceuticals, discusses the 3 pillars of their biopharmaceutical strategy.
  • Summary
  • Transcript
  • Participants
  • Company
Wolfgang Baiker, Corporate Divisions, operations and biopharmaceuticals, discusses the 3 pillars of their biopharmaceutical strategy.
Wolfgang Baiker, Corporate Divisions, operations and biopharmaceuticals, discusses the 3 pillars of their biopharmaceutical strategy.
Wolfgang Baiker
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.